The contribution of hepatic inflammation to chronic diseases such as MASLD (previously known as NAFLD) is supported by the experimental evidence that TNF-α-/- mice and mice treated with a TNF-α receptor antagonist are resistant to hepatic steatosis [34,35]. This evidence concerns the gene TNF and fatty liver disease.